The Coming Copper Bull Run

From Investing Trends | Ad

Copper prices have nearly doubled since last year -- driven by the explosive growth in electric vehicles and soaring demand for green-powered electricity. But copper demand far outpaces supply. Multinational investment banks are predicting a 50% to 100% rise in copper prices by 2025. And this "backdoor" play may be a move to consider.

Find out how you can slip into copper

BPMC Insider Trading (Blueprint Medicines)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.34%

Insider Buying (Last 12 Months): $299,900.00

Insider Selling (Last 12 Months): $11,118,942.19

Blueprint Medicines Insider Trading History Chart

Blueprint Medicines Share Price & Price History

^$55.71

▲ +0.21 (0.38%)

As of 05/19/2022 11:32 AM ET

Days: 30 | 90 | 365

The $193 Billion US-China War You Don't Know About

From Investing Trends | Ad

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

The US-China "Lithium War" Is Creating Opportunity

Blueprint Medicines Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/6/2022	Jeffrey W. Albers	CEO	Sell	5,000	$70.11	$350,550.00	183,243
3/16/2022	L. Becker Hewes	Insider	Sell	2,219	$60.00	$133,140.00
3/10/2022	Ariel Hurley	Insider	Sell	2,339	$57.15	$133,673.85
3/7/2022	Ariel Hurley	Insider	Sell	256	$56.19	$14,384.64
3/3/2022	Ariel Hurley	Insider	Sell	761	$60.27	$45,865.47
3/3/2022	Mark Alan Goldberg	Director	Buy	5,000	$59.98	$299,900.00
12/15/2021	L. Becker Hewes	Insider	Sell	729	$100.00	$72,900.00
12/13/2021	Kate Haviland	COO	Sell	1,000	$98.30	$98,300.00
12/7/2021	Tracey L. Mccain	EVP	Sell	5,000	$97.30	$486,500.00
11/15/2021	Jeffrey W. Albers	CEO	Sell	30,000	$114.50	$3,435,000.00
11/15/2021	L. Becker Hewes	Insider	Sell	729	$115.49	$84,192.21
11/3/2021	Tracey L. Mccain	EVP	Sell	5,000	$110.56	$552,800.00
10/15/2021	L. Becker Hewes	Insider	Sell	729	$102.66	$74,839.14
10/5/2021	Fouad Namouni	Insider	Sell	3,241	$98.18	$318,201.38
9/23/2021	Ariel Hurley	Insider	Sell	600	$110.00	$66,000.00
9/23/2021	Tracey L. Mccain	EVP	Sell	25,000	$108.85	$2,721,250.00
8/19/2021	Jeffrey W. Albers	CEO	Sell	25,000	$92.68	$2,317,000.00
8/17/2021	Ariel Hurley	Insider	Sell	1,350	$91.93	$124,105.50	10,747
6/28/2021	Kate Haviland	COO	Sell	1,000	$90.24	$90,240.00	54,948
5/12/2021	Jeffrey W. Albers	CEO	Sell	25,000	$92.69	$2,317,250.00	179,948
1/4/2021	George Demetri	Director	Sell	758	$112.15	$85,009.70	3,562
12/24/2020	Mark Alan Goldberg	Director	Sell	5,455	$125.00	$681,875.00	9,017
12/17/2020	Charles A Rowland Jr	Director	Sell	10,909	$117.82	$1,285,298.38	14,471
12/1/2020	Mark Alan Goldberg	Director	Sell	5,454	$110.00	$599,940.00	9,016
11/3/2020	Christina Rossi	Insider	Sell	345	$99.69	$34,393.05	20,020
10/16/2020	Kate Haviland	COO	Sell	13,334	$101.23	$1,349,800.82	56,172
10/7/2020	Ariel Hurley	Insider	Sell	600	$100.00	$60,000.00	10,584
10/7/2020	Jeffrey W. Albers	CEO	Sell	5,000	$99.17	$495,850.00	146,434
10/7/2020	Mark Alan Goldberg	Director	Sell	5,454	$100.00	$545,400.00	9,016
9/22/2020	Anthony L Boral	Insider	Sell	6,864	$82.33	$565,113.12	25,828
9/22/2020	George Demetri	Director	Sell	1,704	$85.00	$144,840.00	4,320
9/22/2020	Kate Haviland	COO	Sell	3,143	$85.49	$268,695.07	45,981
9/17/2020	Anthony L Boral	Insider	Sell	23,136	$80.00	$1,850,880.00	28,843
9/17/2020	Nicholas Lydon	Director	Sell	500	$80.00	$40,000.00	47,240
8/17/2020	Ariel Hurley	Insider	Sell	700	$75.00	$52,500.00	10,684
7/6/2020	Nicholas Lydon	Director	Sell	26,007	$80.45	$2,092,263.15	48,340
7/2/2020	Nicholas Lydon	Director	Sell	4,125	$80.16	$330,660.00	76,572
6/22/2020	Nicholas Lydon	Director	Sell	13,017	$80.29	$1,045,134.93	89,039
6/18/2020	Debra Durso-Bumpus	Insider	Sell	2,500	$75.18	$187,950.00	22,005
6/9/2020	Ariel Hurley	Insider	Sell	700	$75.00	$52,500.00	10,684
5/12/2020	Jeffrey W. Albers	CEO	Sell	20,000	$64.67	$1,293,400.00	161,434
3/23/2020	Jeffrey W. Albers	CEO	Sell	20,000	$52.10	$1,042,000.00	141,434
3/23/2020	Marion Dorsch	Insider	Sell	1,214	$52.49	$63,722.86	16,265
1/10/2020	George Demetri	Director	Sell	568	$85.00	$48,280.00	2,462
1/10/2020	Kate Haviland	COO	Sell	7,763	$85.16	$661,097.08	23,628
1/7/2020	George Demetri	Director	Sell	1,705	$80.59	$137,405.95	3,030
12/19/2019	Marion Dorsch	Insider	Sell	4,600	$79.00	$363,400.00	4,600
12/16/2019	Ariel Hurley	Insider	Sell	415	$75.00	$31,125.00	415
12/4/2019	Ariel Hurley	Insider	Sell	192	$77.25	$14,832.00
11/18/2019	Jeffrey W. Albers	CEO	Sell	8,256	$75.42	$622,667.52	66,961
11/8/2019	Jeffrey W. Albers	CEO	Sell	11,744	$74.56	$875,632.64	66,961
10/17/2019	Ariel Hurley	Insider	Sell	415	$75.00	$31,125.00	415
9/16/2019	Ariel Hurley	Insider	Sell	415	$78.14	$32,428.10	415
8/21/2019	Anthony L Boral	Insider	Sell	10,000	$80.07	$800,700.00	1,300
8/19/2019	Jeffrey W. Albers	CEO	Sell	20,000	$81.73	$1,634,600.00	48,961
8/19/2019	Kate Haviland	COO	Sell	95	$85.00	$8,075.00	15,960
8/15/2019	Ariel Hurley	Insider	Sell	415	$84.02	$34,868.30	415
8/15/2019	Lonnel Coats	Director	Sell	10,000	$82.40	$824,000.00	10,000
7/19/2019	Ariel Hurley	Insider	Sell	115	$100.00	$11,500.00	115
7/16/2019	Kate Haviland	COO	Sell	1,571	$95.47	$149,983.37	17,436
7/15/2019	Ariel Hurley	Insider	Sell	830	$94.98	$78,833.40	830
7/8/2019	Anthony L Boral	Insider	Sell	10,000	$93.88	$938,800.00	10,000
6/27/2019	Alexis Borisy	Director	Sell	21,818	$92.01	$2,007,474.18
6/20/2019	Charles A Rowland Jr	Director	Sell	11,818	$95.15	$1,124,482.70	11,818
6/17/2019	Ariel Hurley	Insider	Sell	1,405	$98.22	$137,999.10	830
6/17/2019	George Demetri	Director	Sell	1,136	$98.50	$111,896.00	5,303
6/17/2019	Jeffrey W. Albers	CEO	Sell	5,000	$99.06	$495,300.00	33,961
6/17/2019	Kate Haviland	COO	Sell	11,952	$96.46	$1,152,889.92	12,160
6/13/2019	Ariel Hurley	Insider	Sell	2,733	$88.04	$240,613.32
6/12/2019	Jeffrey W. Albers	CEO	Sell	20,000	$84.75	$1,695,000.00	48,961
6/12/2019	Nicholas Lydon	Director	Sell	25,000	$84.77	$2,119,250.00	166,527

The Coming Copper Bull Run

From Investing Trends | Ad

Find out how you can slip into copper

SEC Filings (Institutional Ownership Changes) for Blueprint Medicines (NASDAQ:BPMC)

99.69% of Blueprint Medicines stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Blueprint Medicines Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/18/2022	BNP Paribas Arbitrage SA	8,468	$0.54M	0.0%	-31.5%	0.014%
5/18/2022	Golden State Equity Partners	2,070	$0.20M	0.1%	N/A	0.003%
5/17/2022	Point72 Hong Kong Ltd	3,313	$0.21M	0.0%	N/A	0.006%
5/17/2022	Quantbot Technologies LP	1,500	$95K	0.0%	N/A	0.003%
5/17/2022	Royal Bank of Canada	7,579	$0.48M	0.0%	-57.6%	0.013%
5/17/2022	Rock Springs Capital Management LP	947,715	$60.54M	1.5%	+10.2%	1.591%
5/17/2022	Eaton Vance Management	105,829	$6.76M	0.0%	-59.8%	0.178%
5/17/2022	Eventide Asset Management LLC	592,500	$37.85M	0.6%	+49.7%	0.995%
5/17/2022	Ensign Peak Advisors Inc	70,624	$4.51M	0.0%	+4.1%	0.119%
5/17/2022	Farallon Capital Management LLC	1,356,987	$86.68M	0.5%	+67.2%	2.278%
5/17/2022	Guggenheim Capital LLC	38,562	$2.46M	0.0%	-3.4%	0.065%
5/16/2022	California State Teachers Retirement System	72,833	$4.65M	0.0%	-7.8%	0.122%
5/16/2022	Goldman Sachs Group Inc.	306,776	$19.60M	0.0%	-23.4%	0.515%
5/16/2022	PDT Partners LLC	3,874	$0.25M	0.0%	N/A	0.007%
5/16/2022	Captrust Financial Advisors	16,206	$1.04M	0.0%	+2.5%	0.027%
5/16/2022	Woodline Partners LP	24,873	$1.59M	0.0%	-59.9%	0.042%
5/16/2022	Wellington Management Group LLP	3,908,944	$249.70M	0.0%	+12.4%	6.562%
5/16/2022	State Street Corp	2,266,894	$144.81M	0.0%	+30.9%	3.805%
5/16/2022	Engineers Gate Manager LP	3,791	$0.24M	0.0%	N/A	0.006%
5/16/2022	Graham Capital Management L.P.	3,927	$0.25M	0.0%	N/A	0.007%
5/16/2022	Cadian Capital Management LP	1,921,347	$122.74M	6.1%	+326.3%	3.225%
5/16/2022	Invesco Ltd.	75,858	$4.85M	0.0%	-21.9%	0.127%
5/16/2022	UBS Group AG	48,303	$3.09M	0.0%	-24.9%	0.081%
5/16/2022	Granahan Investment Management LLC	156,646	$10.01M	0.2%	+208.8%	0.263%
5/16/2022	Novo Holdings A S	227,526	$14.53M	0.6%	+15.5%	0.382%
5/16/2022	Hsbc Holdings PLC	25,681	$1.66M	0.0%	N/A	0.043%
5/13/2022	Renaissance Technologies LLC	68,400	$4.37M	0.0%	N/A	0.115%
5/13/2022	Bellevue Group AG	26,000	$1.66M	0.0%	+2.0%	0.044%
5/13/2022	Northern Trust Corp	579,947	$37.05M	0.0%	-15.4%	0.974%
5/13/2022	Charles Schwab Investment Management Inc.	447,849	$28.61M	0.0%	+2.2%	0.752%
5/13/2022	Nelson Van Denburg & Campbell Wealth Management Group LLC	7,155	$0.46M	0.0%	-5.2%	0.012%
5/13/2022	Affinity Asset Advisors LLC	1,988	$0.13M	0.0%	N/A	0.003%
5/13/2022	First Trust Advisors LP	10,106	$0.65M	0.0%	-81.3%	0.017%
5/13/2022	Prudential Financial Inc.	63,538	$4.06M	0.0%	-42.6%	0.107%
5/13/2022	American International Group Inc.	29,051	$1.86M	0.0%	-6.6%	0.049%
5/13/2022	Tekla Capital Management LLC	97,253	$6.21M	0.2%	N/A	0.163%
5/13/2022	Ergoteles LLC	32,958	$2.11M	0.1%	N/A	0.055%
5/13/2022	Loomis Sayles & Co. L P	438,022	$27.98M	0.0%	+15.5%	0.735%
5/13/2022	Candriam Luxembourg S.C.A.	189,441	$12.10M	0.1%	-46.2%	0.318%
5/13/2022	Vanguard Group Inc.	5,525,060	$352.94M	0.0%	-0.2%	9.275%
5/13/2022	Allianz Asset Management GmbH	62,148	$3.97M	0.0%	-27.1%	0.104%
5/13/2022	Sei Investments Co.	23,110	$1.48M	0.0%	-34.0%	0.039%
5/13/2022	Blair William & Co. IL	3,851	$0.25M	0.0%	-35.3%	0.006%
5/13/2022	Dimensional Fund Advisors LP	554,480	$35.42M	0.0%	+21.4%	0.931%
5/12/2022	Synovus Financial Corp	26,723	$1.70M	0.0%	+24.8%	0.045%
5/12/2022	Integral Health Asset Management LLC	153,000	$9.77M	2.5%	+104.0%	0.257%
5/12/2022	BlackRock Inc.	5,383,138	$343.88M	0.0%	+0.9%	9.037%
5/12/2022	Rhumbline Advisers	63,434	$4.05M	0.0%	+1.5%	0.106%
5/12/2022	Panagora Asset Management Inc.	180,581	$11.54M	0.1%	+2.2%	0.303%
5/12/2022	Metropolitan Life Insurance Co NY	3,677	$0.24M	0.0%	-75.3%	0.006%
5/12/2022	MetLife Investment Management LLC	31,782	$2.03M	0.0%	+53.9%	0.053%
5/12/2022	Capital Fund Management S.A.	43,387	$2.77M	0.0%	N/A	0.073%
5/12/2022	Pitcairn Co.	3,446	$0.22M	0.0%	-17.7%	0.006%
5/12/2022	E Fund Management Co. Ltd.	4,698	$0.30M	0.0%	N/A	0.008%
5/12/2022	Eagle Asset Management Inc.	357,029	$22.81M	0.1%	-7.2%	0.599%
5/12/2022	AlphaCrest Capital Management LLC	7,467	$0.48M	0.0%	N/A	0.013%
5/12/2022	Eagle Health Investments LP	170,551	$10.90M	2.7%	-11.5%	0.286%
5/12/2022	Citigroup Inc.	22,982	$1.47M	0.0%	-63.6%	0.039%
5/12/2022	Hancock Whitney Corp	4,110	$0.26M	0.0%	-9.2%	0.007%
5/11/2022	US Bancorp DE	7,234	$0.46M	0.0%	+11.4%	0.012%
5/11/2022	American Century Companies Inc.	756,725	$48.34M	0.0%	-12.5%	1.270%
5/11/2022	Bank of New York Mellon Corp	247,261	$15.80M	0.0%	-61.6%	0.415%
5/11/2022	William Blair Investment Management LLC	1,085,516	$69.34M	0.2%	-37.9%	1.822%
5/11/2022	Raymond James Financial Services Advisors Inc.	33,374	$2.13M	0.0%	-0.8%	0.056%
5/11/2022	Raymond James & Associates	31,565	$2.02M	0.0%	+18.6%	0.053%
5/11/2022	JPMorgan Chase & Co.	1,675,124	$107.01M	0.0%	+1.9%	2.812%
5/10/2022	Sectoral Asset Management Inc.	81,900	$5.23M	0.9%	+24.5%	0.137%
5/10/2022	Profund Advisors LLC	9,062	$0.58M	0.0%	-10.0%	0.015%
5/10/2022	ProShare Advisors LLC	18,452	$1.18M	0.0%	-18.1%	0.031%
5/10/2022	TD Asset Management Inc.	101,024	$6.45M	0.0%	-4.6%	0.170%
5/10/2022	Van ECK Associates Corp	1,548	$99K	0.0%	+16.0%	0.003%
5/9/2022	Principal Financial Group Inc.	17,019	$1.09M	0.0%	+2.0%	0.029%
5/9/2022	Swiss National Bank	132,100	$8.44M	0.0%	+7.8%	0.222%
5/9/2022	Duality Advisers LP	11,917	$0.76M	0.1%	N/A	0.020%
5/9/2022	Teacher Retirement System of Texas	11,565	$0.74M	0.0%	+9.5%	0.019%
5/9/2022	Brown Advisory Inc.	913,402	$58.58M	0.1%	+4.2%	1.533%
5/6/2022	TimesSquare Capital Management LLC	243,899	$15.58M	0.2%	-82.4%	0.409%
5/5/2022	Aigen Investment Management LP	8,920	$0.57M	0.1%	N/A	0.015%
5/5/2022	EFG Asset Management Americas Corp.	7,865	$0.50M	0.1%	+28.7%	0.013%
5/5/2022	Fisher Asset Management LLC	398,055	$25.43M	0.0%	-0.6%	0.668%
5/5/2022	New York State Common Retirement Fund	50,478	$3.23M	0.0%	+4.2%	0.085%
5/5/2022	Russell Investments Group Ltd.	33,299	$2.13M	0.0%	-25.0%	0.056%
5/4/2022	California Public Employees Retirement System	124,024	$7.92M	0.0%	-4.6%	0.209%
5/4/2022	Advisor Group Holdings Inc.	3,024	$0.19M	0.0%	-8.3%	0.005%
5/4/2022	ClariVest Asset Management LLC	35,146	$2.25M	0.1%	-9.9%	0.059%
5/4/2022	Prospera Financial Services Inc	655	$42K	0.0%	N/A	0.001%
5/4/2022	Victory Capital Management Inc.	7,203	$0.42M	0.0%	-98.2%	0.012%
5/4/2022	Envestnet Asset Management Inc.	12,592	$0.80M	0.0%	-10.0%	0.021%
5/4/2022	NBW Capital LLC	29,543	$1.89M	0.4%	-0.8%	0.050%
5/4/2022	Shell Asset Management Co.	6,745	$0.43M	0.0%	-12.9%	0.011%
5/3/2022	State of New Jersey Common Pension Fund D	38,858	$2.48M	0.0%	+10.6%	0.066%
5/3/2022	Torray LLC	12,489	$0.80M	0.1%	+7.9%	0.021%
5/2/2022	Mutual of America Capital Management LLC	40,615	$2.59M	0.0%	-4.2%	0.069%
5/2/2022	Steward Partners Investment Advisory LLC	617	$39K	0.0%	+414.2%	0.001%
4/29/2022	SG Americas Securities LLC	18,194	$1.16M	0.0%	-49.8%	0.031%
4/29/2022	Nisa Investment Advisors LLC	454	$29K	0.0%	-86.5%	0.001%
4/29/2022	Summit Global Investments	18,582	$1.19M	0.1%	-34.3%	0.031%
4/28/2022	Harbor Capital Advisors Inc.	12,488	$0.80M	0.4%	-12.8%	0.021%
4/28/2022	DekaBank Deutsche Girozentrale	25,150	$1.64M	0.0%	+4.6%	0.042%
4/27/2022	Peregrine Capital Management LLC	126,868	$8.10M	0.2%	+2.6%	0.214%

Data available starting January 2016

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $55.71

$54.32

$55.99

50 Day Range

MA: $62.59

$51.85

$70.15

52 Week Range

Now: $55.71

$50.96

$117.86

Volume

3,106 shs

Average Volume

629,656 shs

Market Capitalization

$3.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Who are the company insiders with the largest holdings of Blueprint Medicines?: Blueprint Medicines' top insider investors include:
Jeffrey W Albers (CEO)
Nicholas Lydon (Director)
Kate Haviland (COO)
Anthony L Boral (Insider)
Debra Durso-Bumpus (Insider)
Christina Rossi (Insider)
Charles A Rowland Jr (Director)
Ariel Hurley (Insider)
Mark Alan Goldberg (Director)
George Demetri (Director)
Fouad Namouni (Insider)
L Becker Hewes (Insider)
Tracey L Mccain (EVP)
Learn More about top insider investors at Blueprint Medicines.
Who are the major institutional investors of Blueprint Medicines?: Blueprint Medicines' top institutional investors include:
Vanguard Group Inc. — 9.27%
BlackRock Inc. — 9.04%
Wellington Management Group LLP — 6.56%
State Street Corp — 3.81%
Cadian Capital Management LP — 3.23%
JPMorgan Chase & Co. — 2.81%
Learn More about top institutional investors of Blueprint Medicines stock.
Which major investors are selling Blueprint Medicines stock?: In the previous quarter, BPMC stock was sold by these institutional investors:
TimesSquare Capital Management LLC
William Blair Investment Management LLC
Bank of New York Mellon Corp
Victory Capital Management Inc.
Candriam Luxembourg S.C.A.
Eaton Vance Management
American Century Companies Inc.
Northern Trust Corp
Within the last year, company insiders that have sold Blueprint Medicines company stock include:
Jeffrey W Albers (CEO)
Nicholas Lydon (Director)
Kate Haviland (COO)
Anthony L Boral (Insider)
Debra Durso-Bumpus (Insider)
Christina Rossi (Insider)
Learn More investors selling Blueprint Medicines stock.
Which major investors are buying Blueprint Medicines stock?: During the last quarter, BPMC stock was bought by institutional investors including:
Cadian Capital Management LP
Farallon Capital Management LLC
State Street Corp
Wellington Management Group LLP
Assenagon Asset Management S.A.
Eventide Asset Management LLC
Granahan Investment Management LLC
Dimensional Fund Advisors LP

The Incredible Dividend Map... Where Stocks Yield 26% a Year!

From Investing Daily | Ad

What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

Get in on the action here.

BPMC Insider Trading (Blueprint Medicines)

Blueprint Medicines Insider Trading History Chart

Blueprint Medicines Share Price & Price History

Blueprint Medicines Insider Trading History

SEC Filings (Institutional Ownership Changes) for Blueprint Medicines (NASDAQ:BPMC)

Institutional Buying and Selling by Quarter

Blueprint Medicines Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Blueprint Medicines?

Who are the major institutional investors of Blueprint Medicines?

Which major investors are selling Blueprint Medicines stock?

Which major investors are buying Blueprint Medicines stock?